

Резюме: Коновалова Елена Валерьевна



Адрес

Федеральное государственное
бюджетное учреждение науки
Институт биоорганической химии им.
академиков М.М. Шемякина и Ю.А.
Овчинникова Российской академии
наук, Москва, Россия

Контакты

<https://www.ibch.ru/users/859>

Работа в ИБХ

2023–наст.вр.	Младший научный сотрудник
2014–2023	Старший инженер

Гранты и проекты

2024– наст.вр.	Онкотераностика и проблемы резистентности к противоопухолевым и антибактериальным препаратам
2018– 2020	Получение токсинов для таргетной терапии рака с использованием методов "клик-химии" и генетической инженерии

Публикации

- Deyev S, Fominykh A, Varvashenya R, Yanovich G, Bodenko V, Plotnikov E, Tretyakova M, Eskova D, Zhelchan R, Schulga A, **Kononova E**, Ziganshin R, Orlova A, Belousov M, Tolmachev V, Larkina M (2026). The Use of Glycine-Containing Peptide-Based Chelators for Labeling with Tc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1. *Mol Pharm* 23 (4), 2469–2480, [10.1021/acs.molpharmaceut.5c01498](https://doi.org/10.1021/acs.molpharmaceut.5c01498)
- Larkina M, Yanovich G, Hasnowo LA, Varvashenya R, Yuldasheva F, Tretyakova M, Plotnikov E, Zelchan R, Schulga A, **Kononova E**, Ziganshin R, Belousov MV, Tolmachev V, Deyev SM (2025). Comparative Preclinical Evaluation of the Tumor-Targeting Properties of Radioiodine and Technetium-Labeled Designed Ankyrin Repeat Proteins for Imaging of Epidermal Growth Factor Receptor Expression in Malignant Tumors. *Int J Mol Sci* 26 (21), 10609, [10.3390/ijms262110609](https://doi.org/10.3390/ijms262110609)
- Kostin NN, Bobik TV, **Kononova EV**, Kocharovskaya MV, Simonova MA, Rushkevich NY, Mokrushina YA, Skryabin GA, Kalinin RS, Kovalchuk SI, Ziganshin RH, Kaluzhskiy LA, Gnedenko OV, Yablokov EO, Ivanov AS, Chernov AS, Kazakov VA, Khokhlova ON, Murashev AN, Hong S, Shramova EI, Schulga AA, Lyukmanova EN, Kirpichnikov MP, Smirnov IV, Belogurov AA, Rubtsov YP, Stepanov AV, Zhang H, Gabibov AG, Deyev SM (2025). Fusion of SARS-CoV-2 neutralizing LCB1 peptide with *Bacillus amyloliquefaciens* RNase improves antiviral efficacy. *Sci Rep* 15 (1), 28039, [10.1038/s41598-025-12444-2](https://doi.org/10.1038/s41598-025-12444-2)
- Vorobyeva A, Din MU, Schulga A, **Kononova E**, Abouzayed A, Bragina O, Li R, Gräslund T, Deyev SM, Oroujeni M (2025). Selection of the optimal chelator for labeling of DARPIn Ec1 with gallium-68 for PET imaging of EpCAM expression. *EJNMMI Radiopharmacy and Chemistry* 10 (1), 26, [10.1186/s41181-025-00347-6](https://doi.org/10.1186/s41181-025-00347-6)
- Tolmachev V, Vorobyeva A, Rosly AHB, Garousi J, Liu Y, Gräslund T, Papalanis E, Schulga A, **Kononova E**, Orlova A, Deyev SM, Oroujeni M (2025). Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture. *Int J Mol Sci* 26 (11), 5236, [10.3390/ijms26115236](https://doi.org/10.3390/ijms26115236)
- Streltsova MA, Boyko AA, Alekseeva NA, Proshkina GM, Shramova EI, Grechikhina MV, Shevchenko MA, Shustova OA, Popodko AI, **Kononova EV**, Schulga AA, Sapozhnikov AM, Deyev SM, Kovalenko EI (2025). Genetically modified NK cells equipped with a switchable CAR for the treatment of HER2-positive cancers.

Biochimie 238 (Pt B), 30–42, [10.1016/j.biochi.2025.07.021](https://doi.org/10.1016/j.biochi.2025.07.021)

7. Varvashenya RN, Yanovich GE, Plotnikov EV, Shulga AA, **Konovalova EV**, Zigashin RH, Deev SM, Brazovskii KS, Belousov MV, Chernov VI, Larkina MS (2025). Development of quality control techniques of chemical precursor – recombinant protein with ankyrin repeats for radionuclide imaging of HER2 overexpression in malignant tumors. *Drug Development and Registration* 14 (4), 138–151, [10.33380/2305-2066-2025-14-4-2043](https://doi.org/10.33380/2305-2066-2025-14-4-2043)
8. Konshina AG, Bocharov EV, **Konovalova EV**, Schulga AA, Tolmachev V, Deyev SM, Efremov RG (2024). Structural Basis of Activity of HER2-Targeting Construct Composed of DARPIn G3 and Albumin-Binding Domains. *Int J Mol Sci* 25 (21), 11370, [10.3390/ijms252111370](https://doi.org/10.3390/ijms252111370)
9. Proshkina GM, Shramova EI, Mirkasyimov AB, Griaznova OY, **Konovalova EV**, Schulga AA, Deyev SM (2024). The Barnase-Barstar-based pre-targeting strategy for enhanced antitumor therapy in vivo. *Biochimie* 228, 158–166, [10.1016/j.biochi.2024.09.011](https://doi.org/10.1016/j.biochi.2024.09.011)
10. Zelchan R, Chernov V, Medvedeva A, Rybina A, Bragina O, Mishina E, Larkina M, Varvashenya R, Fominykh A, Schulga A, **Konovalova E**, Vorobyeva A, Orlova A, Tashireva L, Deyev SM, Tolmachev V (2024). Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [99mTc]Tc(CO)₃-(HE)₃-Ec1 for Visualization of EpCAM-Expressing Lung Cancer. *Cancers (Basel)* 16 (16), 2815, [10.3390/cancers16162815](https://doi.org/10.3390/cancers16162815)
11. Deyev SM, Oroujeni M, Garousi J, Gråslund T, Li R, Rosly AHB, Orlova A, **Konovalova E**, Schulga A, Vorobyeva A, Tolmachev V (2024). Preclinical Evaluation of HER2-Targeting DARPIn G3: Impact of Albumin-Binding Domain (ABD) Fusion. *Int J Mol Sci* 25 (8), 4246, [10.3390/ijms25084246](https://doi.org/10.3390/ijms25084246)
12. Larkina M, Varvashenya R, Yuldasheva F, Plotnikov E, Bezverkhniaia E, Tretyakova M, Zelchan R, Schulga A, **Konovalova E**, Vorobyeva A, Belousov M, Orlova A, Tolmachev V, Deyev S (2024). Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors. *Mol Pharm* 21 (4), 1919–1932, [10.1021/acs.molpharmaceut.3c01173](https://doi.org/10.1021/acs.molpharmaceut.3c01173)
13. Bobik TV, Simonova MA, Rushkevich NU, Kostin NN, Skryabin GA, Knorre VD, Schulga AA, **Konovalova EV**, Proshkina GM, Gabibov AG, Deev SM (2024). Immunoliposomes As a Promising Antiviral Agent against SARS-CoV-2. *Dokl Biochem Biophys* 514 (1), 6–10, [10.1134/S1607672923700618](https://doi.org/10.1134/S1607672923700618)
14. Bragina OD, Tashireva LA, Loos DM, Vtorushin SV, Shulga AA, **Konovalova EN**, Borodina ME, Chernov VI, Tolmachev VM, Deyev SM (2024). Evaluation of HER2/neu Expression in Metastatic Axillary Lymph Node Tissue of Breast Cancer Patients Using [99mTc]Tc-(HE)₃-G3. *Acta Naturae* 16 (2), 22–29, [10.32607/actanaturae.27448](https://doi.org/10.32607/actanaturae.27448)
15. Bragina O, Chernov V, Schulga A, **Konovalova E**, Hober S, Deyev S, Sörensen J, Tolmachev V (2023). Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)₃-G3, for Imaging of HER2-Positive Breast Cancer. *Cancers (Basel)* 15 (12), 3149, [10.3390/cancers15123149](https://doi.org/10.3390/cancers15123149)
16. Xu T, Schulga A, **Konovalova E**, Rinne SS, Zhang H, Vorontsova O, Orlova A, Deyev SM, Tolmachev V, Vorobyeva A (2023). Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPIn–Toxin Fusion in a Pancreatic Cancer Xenograft Model. *Int J Mol Sci* 24 (3), 2838, [10.3390/ijms24032838](https://doi.org/10.3390/ijms24032838)
17. Kalinin RS, Shipunova VO, Rubtsov YP, Ukrainskay VM, Schulga A, **Konovalova EV**, Volkov DV, Yaroshevich IA, Moysenovich AM, Belogurov AA, Telegin GB, Chernov AS, Maschan MA, Terekhov SS, Knorre VD, Khurs E, Gnuchev NV, Gabibov AG, Deyev SM (2023). Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy. *Dokl Biochem Biophys* 508 (1), 17–20, [10.1134/S1607672922700041](https://doi.org/10.1134/S1607672922700041)
18. Yashchenok AM, Chernyshev VS, **Konovalova EV**, Kholodenko R, Tsydenzhapova E, Shipunova VO, Schulga AA, Deyev SM, Gorin DA (2023). Anti-CD63-Oligonucleotide Functionalized Magnetic Beads for the Rapid Isolation of Small Extracellular Vesicles and Detection of EpCAM and HER2 Membrane Receptors using DARPIn Probes. *Anal Sens* 3 (1), , [10.1002/anse.202200059](https://doi.org/10.1002/anse.202200059)
19. Balalaeva IV, Krylova LV, Karpova MA, Shulga AA, **Konovalova EV**, Guryev EL, Deyev SM (2022). Synergistic Effect of the Combined Action of Targeted and Photodynamic Therapy on HER2-Positive Breast Cancer. *Dokl Biochem Biophys* 507 (1), 330–333, [10.1134/S1607672922340038](https://doi.org/10.1134/S1607672922340038)
20. Abakumova TO, Gusliakova OI, Cvjetinovic J, Efimova OI, **Konovalova EV**, Schulga AA, Zatselin TS, Gorin DA, Yashchenok AM, Deyev SM (2022). Barnase-Loaded Vaterite Nanoparticles Functionalized by EpCAM

- Targeting Vectors for the Treatment of Lung Diseases. *ACS Applied Nano Materials* 5 (8), 10744–10754, [10.1021/acsanm.2c02078](https://doi.org/10.1021/acsanm.2c02078)
21. Tolmachev V, Bodenko V, Oroujeni M, Deyev S, **Konovalova E**, Schulga A, Lindbo S, Hober S, Bragina O, Orlova A, Vorobyeva A (2022). Direct In Vivo Comparison of 99mTc-Labeled Scaffold Proteins, DARPIn G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy. *Int J Mol Sci* 23 (23), 15181, [10.3390/ijms232315181](https://doi.org/10.3390/ijms232315181)
 22. Stepanov AV, Kalinin RS, Shipunova VO, Zhang D, Xie J, Rubtsov YP, Ukrainskaya VM, Schulga A, **Konovalova EV**, Volkov DV, Yaroshevich IA, Moysenovich AM, Belogurov AA, Zhang H, Telegin GB, Chernov AS, Maschan MA, Terekhov SS, Wu P, Deyev SM, Lerner RA, Gabibov AG, Altman S (2022). Switchable targeting of solid tumors by BsCAR T cells. *Proc Natl Acad Sci U S A* 119 (46), e2210562119, [10.1073/pnas.2210562119](https://doi.org/10.1073/pnas.2210562119)
 23. Larkina M, Plotnikov E, Bezverkhniaia E, Shabanova Y, Tretyakova M, Yuldasheva F, Zelchan R, Schulga A, **Konovalova E**, Vorobyeva A, Garousi J, Gräslund T, Belousov M, Tolmachev V, Deyev S (2022). Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPIn G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer. *Int J Mol Sci* 23 (21), , [10.3390/ijms232113443](https://doi.org/10.3390/ijms232113443)
 24. Novoselova MV, Shramova EI, Sergeeva OV, Shcherbinina EY, Perevoschikov SV, Melnikov P, Griaznova OY, Sergeev IS, **Konovalova EV**, Schulga AA, Proshkina GM, Zatsepin TS, Deyev SM, Gorin DA (2022). Polymer/magnetite carriers functionalized by HER2-DARPIn: Avoiding lysosomes during internalization and controlled toxicity of doxorubicin by focused ultrasound induced release. *Nanomedicine* 47, 102612, [10.1016/j.nano.2022.102612](https://doi.org/10.1016/j.nano.2022.102612)
 25. Novoselova M, Chernyshev VS, Schulga A, **Konovalova EV**, Chuprov-Netochin RN, Abakumova TO, German S, Shipunova VO, Mokrousov MD, Prikhozhdenko E, Bratashov DN, Nozdriukhin DV, Bogorodskiy A, Grishin O, Kosolobov SS, Khlebtsov BN, Inozemtseva O, Zatsepin TS, Deyev SM, Gorin DA (2022). Effect of Surface Modification of Multifunctional Nanocomposite Drug Delivery Carriers with DARPIn on Their Biodistribution In Vitro and In Vivo. *ACS Applied Bio Materials* 5 (6), 2976–2989, [10.1021/acsabm.2c00289](https://doi.org/10.1021/acsabm.2c00289)
 26. Xu T, Liu Y, Schulga A, **Konovalova E**, Deyev SM, Tolmachev V, Vorobyeva A (2022). Epithelial cell adhesion molecule-targeting designed ankyrin repeat protein-toxin fusion Ec1-LoPE exhibits potent cytotoxic action in prostate cancer cells. *Oncol Rep* 47 (5), , [10.3892/or.2022.8305](https://doi.org/10.3892/or.2022.8305)
 27. Bragina OD, Chernov VI, Deyev SM, Vorobyeva AG, **Konovalova EV**, Orlova AM, Shulga AA, Garbukhov EY, Zelchan RV, Medvedeva AA, Tolmachev VM (2022). THE FIRST EXPERIENCE OF CLINICAL USE 99mTc-DARPInG3 FOR RADIONUCLIDE DIAGNOSIS OF BREAST CANCER WITH HER2/neu OVEREXPRESSION. *Meditsinskaya Radiologiya i Radiatsionnaya Bezopasnost* 67 (2), 38–42, [10.33266/1024-6177-2022-67-2-38-42](https://doi.org/10.33266/1024-6177-2022-67-2-38-42)
 28. Yashchenok AM, Gusliakova OI, **Konovalova EV**, Novoselova MV, Shipunova VO, Abakumova TO, Efimova OI, Kholodenko R, Schulga AA, Zatsepin TS, Gorin DA, Deyev SM (2021). Barnase encapsulation into submicron porous CaCO₃ particles: studies of loading and enzyme activity. *J Mater Chem B Mater Biol Med* 9 (42), 8823–8831, [10.1039/d1tb01315g](https://doi.org/10.1039/d1tb01315g)
 29. Bragina O, Chernov V, Schulga A, **Konovalova E**, Garbukov E, Vorobyeva A, Orlova A, Tashireva L, Sorensen J, Zelchan R, Medvedeva A, Deyev S, Tolmachev V (2021). Phase I trial of 99mTc-(HE)3-G3, a DARPIn-based probe for imaging of HER2 expression in breast cancer. *J Nucl Med* 63 (4), 528–535, [10.2967/jnumed.121.262542](https://doi.org/10.2967/jnumed.121.262542)
 30. Xu T, Vorobyeva A, Schulga A, **Konovalova E**, Vorontsova O, Ding H, Gräslund T, Tashireva LA, Orlova A, Tolmachev V, Deyev SM (2021). Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model. *Cancers (Basel)* 13 (16), , [10.3390/cancers13163939](https://doi.org/10.3390/cancers13163939)
 31. Deyev SM, Xu T, Liu Y, Schulga A, **Konovalova E**, Garousi J, Rinne SS, Larkina M, Ding H, Gräslund T, Orlova A, Tolmachev V, Vorobyeva A (2021). Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPIn Ec1. *Cancers (Basel)* 13 (14), , [10.3390/cancers13143589](https://doi.org/10.3390/cancers13143589)
 32. Vorobyeva A, Bezverkhniaia E, **Konovalova E**, Schulga A, Garousi J, Vorontsova O, Abouzayed A, Orlova A, Deyev S, Tolmachev V (2020). Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPIn Ec1. *Molecules* 25 (20), , [10.3390/molecules25204719](https://doi.org/10.3390/molecules25204719)

33. Shramova E, Proshkina G, Shipunova V, Ryabova A, Kamyshinsky R, Konevega A, Schulga A, **Konovalova E**, Telegin G, Deyev S (2020). Dual targeting of cancer cells with darpin-based toxins for overcoming tumor escape. *Cancers (Basel)* 12 (10), 1–15, [10.3390/cancers12103014](https://doi.org/10.3390/cancers12103014)
34. Guryev EL, Smyshlyaeva AS, Shilyagina NY, Sokolova EA, Shanwar S, Kostyuk AB, Lyubeshkin AV, Schulga AA, **Konovalova EV**, Lin Q, Roy I, Balalaeva IV, Deyev SM, Zvyagin AV (2020). UCNP-based photoluminescent nanomedicines for targeted imaging and theranostics of cancer. *Molecules* 25 (18), , [10.3390/molecules25184302](https://doi.org/10.3390/molecules25184302)
35. Guryev EL, Smyshlyaeva AS, Shilyagina NY, Shanwar S, Kostyuk AB, Shulga AA, **Konovalova EV**, Zvyagin AV, Deyev SM, Petrov RV (2020). Multifunctional Complexes Based on Photoluminescent Upconversion Nanoparticles for Theranostics of the HER2-Positive Tumors. *Dokl Biochem Biophys* 491 (1), 73–76, [10.1134/S160767292002009X](https://doi.org/10.1134/S160767292002009X)
36. Vorobyeva A, **Konovalova E**, Xu T, Schulga A, Altai M, Garousi J, Rinne SS, Orlova A, Tolmachev V, Deyev S (2020). Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPIn Ec1. *Int J Mol Sci* 21 (9), , [10.3390/ijms21093310](https://doi.org/10.3390/ijms21093310)
37. Khodarovich YM, **Konovalova EV**, Schulga AA, Deyev SM, Petrov RV (2020). Removal of the Translocation Domain and the Furin Cleavage Site Decreases the Relative Hepatotoxicity of the Targeted Antitumor Toxins. *Dokl Biochem Biophys* 489 (1), 370–372, [10.1134/S1607672919060048](https://doi.org/10.1134/S1607672919060048)
38. Deyev SM, Vorobyeva A, Schulga A, Abouzayed A, Günther T, Garousi J, **Konovalova E**, Ding H, Gräslund T, Orlova A, Tolmachev V (2019). Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPIn Ec1. *Int J Biol Macromol* 145, 216–225, [10.1016/j.ijbiomac.2019.12.147](https://doi.org/10.1016/j.ijbiomac.2019.12.147)
39. Vorobyeva A, Schulga A, **Konovalova E**, Güler R, Löfblom J, Sandström M, Garousi J, Chernov V, Bragina O, Orlova A, Tolmachev V, Deyev SM (2019). Optimal composition and position of histidine-containing tags improves biodistribution of Tc-labeled DARPIn G3. *Sci Rep* 9 (1), 9405, [10.1038/s41598-019-45795-8](https://doi.org/10.1038/s41598-019-45795-8)
40. Vorobyeva A, Schulga A, **Konovalova E**, Güler R, Mitran B, Garousi J, Rinne S, Löfblom J, Orlova A, Deyev S, Tolmachev V (2019). Comparison of tumor-targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPIn) G3 variants for molecular imaging of HER2. *Int J Oncol* 54 (4), 1209–1220, [10.3892/ijo.2019.4712](https://doi.org/10.3892/ijo.2019.4712)
41. **Konovalova EV**, Shulga AA, Chumakov SP, Khodarovich YM, Woo EJ, Deev SM (2017). Stably Fluorescent Cell Line of Human Ovarian Epithelial Cancer Cells SK-OV-3ip-red. *Bull Exp Biol Med* 164 (1), 99–101, [10.1007/s10517-017-3933-5](https://doi.org/10.1007/s10517-017-3933-5)
42. **Konovalova EV**, Schulga AA, Lukyanova TI, Woo EJ, Deyev SM (2017). Data of self-made Taq DNA polymerase prepared for screening purposes. *Data Brief* 11, 546–551, [10.1016/j.dib.2017.03.004](https://doi.org/10.1016/j.dib.2017.03.004)